BOOK
Hepatitis C Infection as a Systemic Disease:Extra-HepaticManifestation of Hepatitis C, An Issue of Clinics in Liver Disease, E-Book
(2017)
Additional Information
Book Details
Abstract
Dr. Younossi is a highly-esteemed expert in Hepatitis C Virus (HCV), and for the first time in Clinics in Liver Disease, he has compiled articles that specifically address the extrahepatic manifestation of HCV. Articles are specifically devoted to the following topics: Hepatitis C: A Systemic Disease; Rheumatologic Manifestations of HCV; Cardiovascular Manifestations on HCV; Metabolic Manifestations of HCV (DM, Dyslipidemia); Renal Manifestations of HCV; Lymphoproliferative Disorders Associated with HCV; Depression and HCV; Neurologic Manifestations of HCV; Non-HCC Malignancies in HCV; Dermatologic Manifestations of HCV; Fatigue and Patient-reported Outcomes in HCV; Economic Burden of HCV; and Endocrine Manifestations of HCV (non-dabetes). The thorough coverage of systemic issues will give clinicians the information they need to effectively manage the HCV patient with other health issues.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Hepatitis C Infection as aSystemic Disease: Extra-HepaticManifestation of Hepatitis C\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface | vii | ||
| Hepatitis C Infection: A Systemic Disease | vii | ||
| Rheumatologic Manifestations of Hepatitis C Virus Infection | vii | ||
| Cardiovascular Manifestations of Hepatitis C Virus | vii | ||
| Metabolic Manifestations of Hepatitis C Virus: Diabetes Mellitus, Dyslipidemia | viii | ||
| Renal Manifestations of Hepatitis C Virus | viii | ||
| Hepatitis C Virus–Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment | viii | ||
| Chronic Hepatitis C Virus Infection and Depression | viii | ||
| Neurologic Manifestations of Hepatitis C Virus Infection | ix | ||
| Hepatitis C and Risk of Nonhepatic Malignancies | ix | ||
| Dermatologic Manifestations of Chronic Hepatitis C Infection | ix | ||
| Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection | x | ||
| Economic Burden of Hepatitis C Infection | x | ||
| Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation | x | ||
| Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabet ... | x | ||
| Treatment of Extrahepatic Manifestations of Hepatitis C Virus | xi | ||
| CLINICS IN LIVER DISEASE\r | xii | ||
| FORTHCOMING ISSUES | xii | ||
| November 2017 | xii | ||
| February 2018 | xii | ||
| May 2018 | xii | ||
| RECENT ISSUES | xii | ||
| May 2017 | xii | ||
| February 2017 | xii | ||
| November 2016 | xii | ||
| Preface | xiii | ||
| Hepatitis C Infection | 449 | ||
| Key points | 449 | ||
| REFERENCES | 450 | ||
| Rheumatologic Manifestations of Hepatitis C Virus Infection | 455 | ||
| Key points | 455 | ||
| HEPATITIS C VIRUS AND ARTHRALGIA/MYALGIA | 456 | ||
| HEPATITIS C VIRUS–RELATED MIXED CRYOGLOBULINEMIA VASCULITIS | 456 | ||
| HEPATITIS C VIRUS AND SICCA SYNDROME | 456 | ||
| HEPATITIS C VIRUS AND FIBROMYALGIA/FATIGUE | 457 | ||
| HEPATITIS C VIRUS AND THE PRODUCTION OF AUTOANTIBODIES | 457 | ||
| UNDERLYING MECHANISMS LEADING TO RHEUMATOLOGIC MANIFESTATIONS IN HEPATITIS C VIRUS–INFECTED PATIENTS | 457 | ||
| IMPACT OF HEPATITIS C VIRUS INFECTION ON RHEUMATOLOGIC DISEASES | 458 | ||
| INCREASED CARDIOMETABOLIC MORBIDITY AND MORTALITY IN HEPATITIS C VIRUS–INFECTED PATIENTS | 458 | ||
| TREATMENT OF HEPATITIS C VIRUS INFECTION AND ASSOCIATED RHEUMATOLOGIC MANIFESTATIONS | 459 | ||
| SUMMARY | 460 | ||
| REFERENCES | 460 | ||
| Cardiovascular Manifestations of Hepatitis C Virus | 465 | ||
| Key points | 465 | ||
| INTRODUCTION | 465 | ||
| HEPATITIS C VIRUS AND CARDIOVASCULAR MORTALITY | 467 | ||
| HEPATITIS C VIRUS AND SPECIFIC CARDIOVASCULAR DISEASE MANIFESTATIONS | 467 | ||
| Hepatitis C Virus Infection and Carotid Atherosclerosis | 467 | ||
| Hepatitis C Virus Infection and Cerebrovascular Events | 468 | ||
| Hepatitis C Virus Infection and Coronary Artery Disease | 468 | ||
| HEPATITIS C VIRUS INFECTION AND INSULIN RESISTANCE | 469 | ||
| IMPACT OF HEPATITIS C VIRUS SUSTAINED VIROLOGICAL RESPONSE ON CARDIOVASCULAR DISEASE | 469 | ||
| PATHOGENESIS OF HEPATITIS C VIRUS–INDUCED CARDIOVASCULAR INJURY | 470 | ||
| SUMMARY | 471 | ||
| REFERENCES | 471 | ||
| Metabolic Manifestations of Hepatitis C Virus | 475 | ||
| Key points | 475 | ||
| HEPATITIS C VIRUS, LIPID METABOLISM, AND HEPATIC STEATOSIS | 476 | ||
| Hepatitis C Virus–Related Steatosis: Prevalence and Risk Factors | 476 | ||
| Pathogenic Mechanisms of Hepatitis C Virus–Related Steatosis | 476 | ||
| HEPATITIS C VIRUS, TYPE 2 DIABETES, AND INSULIN RESISTANCE | 477 | ||
| Prevalence and Risk Factors | 477 | ||
| Mechanisms of Hepatitis C Virus–Induced Insulin Resistance | 480 | ||
| Hepatitis C virus effects on insulin signaling pathway in the liver | 480 | ||
| Proinflammatory cytokines and hepatitis C virus–mediated insulin resistance | 480 | ||
| Reactive oxygen species and hepatitis C virus–mediated insulin resistance | 481 | ||
| Incretin and hepatitis C virus–mediated insulin resistance | 481 | ||
| Effect of hepatitis C virus on pancreatic ß-cells | 481 | ||
| REFERENCES | 482 | ||
| Renal Manifestations of Hepatitis C Virus | 487 | ||
| Key points | 487 | ||
| INTRODUCTION | 487 | ||
| HEPATIATIS C VIRUS–ASSOCIATED RENAL DISEASE | 489 | ||
| Histopathologic Features | 489 | ||
| Etiopathogenesis | 489 | ||
| Clinical Aspects | 491 | ||
| Isolated hepatitis C virus–related renal disease | 491 | ||
| Renal involvement plus other hepatitis C virus extrahepatic manifestations | 491 | ||
| Renal involvement and cryoglobulinemic vasculitis | 492 | ||
| Renal dysfunction in hepatitis C virus–related liver cirrhosis | 493 | ||
| DIAGNOSIS | 493 | ||
| PROGNOSIS | 493 | ||
| TREATMENT | 494 | ||
| REFERENCES | 496 | ||
| Hepatitis C Virus–Associated Non-Hodgkin Lymphomas | 499 | ||
| Key points | 499 | ||
| INTRODUCTION | 499 | ||
| BIOLOGY OF HEPATITIS C VIRUS–POSITIVE LYMPHOPROLIFERATIVE DISORDERS | 500 | ||
| THE EPIDEMIOLOGY OF HEPATITIS C VIRUS–NON-HODGKIN LYMPHOMA | 503 | ||
| THE TREATMENT OF HEPATITIS C VIRUS–ASSOCIATED NON-HODGKIN LYMPHOMA | 504 | ||
| REFERENCES | 508 | ||
| Chronic Hepatitis C Virus Infection and Depression | 517 | ||
| Key points | 517 | ||
| INTRODUCTION | 517 | ||
| HEPATITIS C VIRUS AND DEPRESSION | 518 | ||
| EPIDEMIOLOGY OF DEPRESSION IN CHRONIC HEPATITIS C VIRUS–POSITIVE PATIENTS | 519 | ||
| DEPRESSION AND IMPACT ON QUALITY OF LIFE AND CLINICAL MANAGEMENT OF PATIENTS WITH HEPATITIS C VIRUS | 520 | ||
| MECHANISMS INVOLVED IN HEPATITIS C VIRUS–ASSOCIATED DEPRESSION | 522 | ||
| THERAPEUTIC APPROACHES | 524 | ||
| SUMMARY AND PERSPECTIVES | 525 | ||
| REFERENCES | 526 | ||
| Neurologic Manifestations of Hepatitis C Virus Infection | 535 | ||
| Key points | 535 | ||
| INTRODUCTION | 535 | ||
| Cognitive Impairment: Pathophysiology | 535 | ||
| Cognitive impairment: clinical manifestations | 536 | ||
| Cognitive impairment and comorbidities | 536 | ||
| Cognitive impairment: electroencephalogram and imaging studies | 537 | ||
| Cognitive impairment and hepatitis C virus treatment | 537 | ||
| Interferon treatment | 538 | ||
| Direct-acting antiviral treatment ± ribavirin | 538 | ||
| Direct-acting antiviral treatment: no ribavirin | 539 | ||
| Hepatitis C virus and cerebrovascular disease | 539 | ||
| SUMMARY | 540 | ||
| REFERENCES | 540 | ||
| Hepatitis C and Risk of Nonhepatic Malignancies | 543 | ||
| Key points | 543 | ||
| INTRODUCTION | 543 | ||
| CHOLANGIOCARCINOMA | 544 | ||
| Biologic Mechanism | 544 | ||
| Epidemiologic Observations: Hepatitis C Virus–Cholangiocarcinomas Association | 545 | ||
| Summary | 545 | ||
| PANCREATIC ADENOCARCINOMA | 545 | ||
| Biologic Mechanism | 545 | ||
| Epidemiologic Observations: Hepatitis C Virus–Pancreatic Cancer Association | 546 | ||
| Summary | 546 | ||
| PAPILLARY THYROID CANCER | 546 | ||
| Biologic Mechanism | 546 | ||
| Epidemiologic Evidence: Hepatitis C Virus–Papillary Thyroid Cancer | 547 | ||
| Summary | 547 | ||
| ORAL SQUAMOUS CELL CANCER | 547 | ||
| Biologic Mechanism | 548 | ||
| Epidemiologic Evidence: Hepatitis C Virus–Oral Squamous Cell Cancer Association | 548 | ||
| Summary | 548 | ||
| RENAL CELL CARCINOMA/KIDNEY CANCER | 549 | ||
| Biologic Mechanism | 549 | ||
| Epidemiologic Evidence: Hepatitis C Virus–Renal/Kidney Cancer Association | 549 | ||
| Summary | 550 | ||
| OVERALL SUMMARY | 550 | ||
| REFERENCES | 550 | ||
| Dermatologic Manifestations of Chronic Hepatitis C Infection | 555 | ||
| Key points | 555 | ||
| INTRODUCTION | 555 | ||
| MIXED CRYOGLOBULINEMIA | 556 | ||
| LICHEN PLANUS | 557 | ||
| PORPHYRIA CUTANEA TARDA | 558 | ||
| OTHER DERMATOLOGIC ENTITIES | 559 | ||
| Psoriasis | 559 | ||
| Necrolytic Acral Erythema | 560 | ||
| Pruritus | 560 | ||
| SUMMARY | 560 | ||
| REFERENCES | 561 | ||
| Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection | 565 | ||
| Key points | 565 | ||
| INTRODUCTION | 565 | ||
| Definition of Fatigue | 566 | ||
| HOW COMMON IS FATIGUE? | 566 | ||
| MANIFESTATIONS OF FATIGUE | 566 | ||
| CLASSIFICATION OF FATIGUE | 567 | ||
| PERIPHERAL FATIGUE | 568 | ||
| CENTRAL FATIGUE | 568 | ||
| DIAGNOSTICS FOR FATIGUE | 569 | ||
| TREATMENT | 570 | ||
| IMPACT OF TREATMENT OF HEPATITIS C VIRUS | 571 | ||
| HEALTH-RELATED QUALITY OF LIFE | 571 | ||
| HEALTH-RELATED QUALITY OF LIFE BEFORE, DURING, AND AFTER TREATMENT | 572 | ||
| IMPACT OF DIFFERENT TREATMENT OPTIONS ON HEALTH-RELATED QUALITY OF LIFE | 572 | ||
| SUMMARY | 573 | ||
| REFERENCES | 573 | ||
| Economic Burden of Hepatitis C Infection | 579 | ||
| Key points | 579 | ||
| INTRODUCTION | 579 | ||
| ECONOMICS OF CHRONIC HEPATITIS C TREATMENT | 580 | ||
| THE COST OF HEPATITIS C VIRUS-RELATED LIVER DISEASE | 582 | ||
| ECONOMIC BURDEN OF THE EXTRAHEPATIC MANIFESTATIONS OF HEPATITIS C VIRUS | 584 | ||
| ECONOMIC BURDEN OWING TO WORK PRODUCTIVITY LOSSES IN HEPATITIS C VIRUS–INFECTED SUBJECTS | 585 | ||
| OTHER ASPECTS OF HEPATITIS C VIRUS ECONOMICS | 586 | ||
| SUMMARY | 587 | ||
| REFERENCES | 587 | ||
| Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation | 595 | ||
| Key points | 595 | ||
| INTRODUCTION | 595 | ||
| METABOLIC ABNORMALITIES | 596 | ||
| LYMPHOPROLIFERATIVE DISORDERS | 598 | ||
| RENAL DISORDERS | 599 | ||
| MIXED CRYOGLOBULINEMIA | 600 | ||
| HEALTH-RELATED QUALITY OF LIFE | 601 | ||
| SUMMARY | 601 | ||
| REFERENCES | 602 | ||
| Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabet ... | 607 | ||
| Key points | 607 | ||
| INTRODUCTION | 607 | ||
| Pulmonary Manifestations of Hepatitis C Virus Infection | 608 | ||
| Lung function and obstructive lung diseases | 608 | ||
| Pulmonary hypertension | 608 | ||
| Lung transplantation | 614 | ||
| Lung cancer | 614 | ||
| Pulmonary embolism | 615 | ||
| Pulmonary fibrosis | 615 | ||
| Pulmonary sarcoidosis | 615 | ||
| Tuberculosis | 616 | ||
| Idiopathic Thrombocytopenic Purpura in Hepatitis C Virus–Infected Patients | 616 | ||
| Nondiabetic Endocrine Manifestations of Hepatitis C Virus Infection | 618 | ||
| Thyroid disease | 618 | ||
| Autoimmune thyroiditis | 618 | ||
| Thyroid cancer | 623 | ||
| Interaction with sexual hormones: Infertility, reproduction, menopause, and pregnancy | 623 | ||
| Adrenal insufficiency | 624 | ||
| Growth hormone and insulin-like growth factor | 624 | ||
| Bone health | 624 | ||
| SUMMARY | 625 | ||
| REFERENCES | 625 | ||
| Treatment of Extrahepatic Manifestations of Hepatitis C Virus | 631 | ||
| Key points | 631 | ||
| INTRODUCTION | 632 | ||
| MIXED CRYOGLOBULINEMIA | 632 | ||
| HEPATITIS C VIRUS–RELATED LYMPHOPROLIFERATIVE DISORDERS | 634 | ||
| HEPATITIS C VIRUS–RELATED RENAL DISEASE | 637 | ||
| TYPE 2 DIABETES AND CARDIOVASCULAR OUTCOMES | 639 | ||
| QUALITY OF LIFE AND NEUROCOGNITIVE FUNCTION | 639 | ||
| CUTANEOUS MANIFESTATIONS | 640 | ||
| SUMMARY | 640 | ||
| REFERENCES | 640 |